Compare HMN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | MESO |
|---|---|---|
| Founded | 1945 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1996 | 2005 |
| Metric | HMN | MESO |
|---|---|---|
| Price | $44.94 | $14.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $56.50 | $37.00 |
| AVG Volume (30 Days) | ★ 260.2K | 152.2K |
| Earning Date | 11-03-2026 | 08-26-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ 57.26 | N/A |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $1,701,400,000.00 | N/A |
| Revenue This Year | $3.85 | $58.89 |
| Revenue Next Year | $17.18 | $58.93 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $41.29 | $13.05 |
| 52 Week High | $55.56 | $21.50 |
| Indicator | HMN | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 25.03 | 40.06 |
| Support Level | $41.72 | $14.18 |
| Resistance Level | $45.50 | $16.06 |
| Average True Range (ATR) | 0.94 | 0.40 |
| MACD | -0.34 | -0.08 |
| Stochastic Oscillator | 4.59 | 9.78 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.